Safety and Tolerability of PCSK9 Inhibitors: Current Insights

The current era of preventive cardiology continues to emphasize on low-density lipoprotein cholesterol (LDL-C) reduction to alleviate the burden of atherosclerotic cardiovascular disease (ASCVD). In this regard, the pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosmas, Constantine E, Skavdis, Andreas, Sourlas, Andreas, Papakonstantinou, Evangelia J, Peña Genao, Edilberto, Echavarria Uceta, Rogers, Guzman, Eliscer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737942/
https://www.ncbi.nlm.nih.gov/pubmed/33335431
http://dx.doi.org/10.2147/CPAA.S288831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737942/
https://www.ncbi.nlm.nih.gov/pubmed/33335431
http://dx.doi.org/10.2147/CPAA.S288831

Ejemplares similares